Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cadonilimab plus Anlotinib in Advanced Melanoma
NCT06327698Phase 2Not yet recruiting
- Sponsor
- Hunan Cancer Hospital
- Start
- May 2024
- Primary completion
- May 2026
- Modality
- Bispecific Antibodies
01
Overview
A Phase 2 trial of cadonilimab in melanoma, sponsored by Hunan Cancer Hospital. Planned start May 2024; status: not yet recruiting.
02
Drugs
cadonilimab
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT06327698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06327698.